Viktoria Gavrilina / Shutterstock.com
Pluristem develops therapies using cells from the placenta that have been cultured in a unique way. LSIPR finds out how the company protects and nourishes its technologies.
Several years after scientists found a way to harvest stem cells efficiently from the placenta after birth, companies are turning to it increasingly as a source for cell-based therapies.
The organ that for nine months keeps both mother and baby healthy during pregnancy and which, further research suggests, also plays a role in their long-term health, is a rich source of stem cells.
However, so understudied is the placenta that the Maryland-based Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH) has announced a Human Placenta Project, an initiative aimed at “unlocking the secrets” of the one-pound (500g) organ.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pluristern; stem cells; cell-based therapies; NIH
